NCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT05384015 2025-04-10
PEERS
Fundación GECP
Phase 2 Recruiting
NCT06068153 2024-11-20
AMBER
ETOP IBCSG Partners Foundation
Phase 2 Withdrawn
NCT04287829 2024-11-05
PEMMELA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT04951947 2024-09-19
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05258279 2024-08-28
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
Juntendo University
Phase 2 Active not recruiting
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT05832827 2023-10-23
Artemis
National Cancer Center, Japan
Phase 2 Recruiting
NCT06028633 2023-09-13
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Phase 2 Not yet recruiting
NCT04875585 2022-08-24
INNWOP1
Medical University Innsbruck
Phase 2 Recruiting
NCT04989322 2021-12-08
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
The University of Hong Kong
Phase 2 Unknown
NCT01529112 2017-09-26
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
Eisai Inc.
Phase 2 Completed